NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹119 Cr | ₹87 Cr | ₹58 Cr | ₹66 Cr | ₹42 Cr |
What is the latest Total Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹119 Cr |
| Mar2024 | ₹87 Cr |
| Mar2023 | ₹58 Cr |
| Mar2022 | ₹66 Cr |
| Mar2021 | ₹42 Cr |
How is Total Current Liabilities of NGL FINECHEM Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹119 Cr | 37.40 | |
| Mar2024 | ₹87 Cr | 48.54 | |
| Mar2023 | ₹58 Cr | -11.21 | |
| Mar2022 | ₹66 Cr | 57.19 | |
| Mar2021 | ₹42 Cr | - | |
Compare Total Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,390.0 Cr | 1.4% | -4.8% | 106.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹396,370.0 Cr | -3.9% | -8.9% | -3.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,193.0 Cr | 3.8% | -4.7% | 11.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹141,438.0 Cr | 3.2% | -5.6% | 26.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,097.0 Cr | 3.3% | -6% | 11% | Stock Analytics | |
| CIPLA | ₹97,846.7 Cr | 0.8% | -9.1% | -13.1% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 1.4% |
-4.8% |
106.1% |
| SENSEX | 3.7% |
-0.9% |
0.7% |
You may also like the below Video Courses